Switzerland-based CRO PSI said it has been selected by Synta Pharmaceuticals to conduct its GALAXY-2 trial, a randomized, phase III study of Ganetespib in combination with Docetaxel versus Docetaxel alone in patients with advanced non-small cell lung cancer. PSI currently is initiating this 500-patient study across 15-plus countries.
PSI has been conducting clinical trials in oncology since 1994. Lung cancer represents one of the central indications in PSI’s portfolio. PSI operates globally with 1,200 employees.
Synta Pharmaceuticals, based in Lexington, Mass., focuses on discovering, developing and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a pipeline of small molecule drug candidates with novel chemical structures and distinct mechanisms of action, all invented internally by Synta scientists using their compound library and discovery capabilities.